Clinical Trials Logo

Filter by:
NCT ID: NCT03303118 Completed - Cerebral Hypoxia Clinical Trials

The Effects of Hypobaria vs Hypoxia on Cerebral Functions.

Hypoxia
Start date: November 16, 2017
Phase: N/A
Study type: Interventional

The investigators will investigate the effect of hypobaria and hypoxia on physiological responses such as: oxygen saturation, heart rate, cerebral blood flow, cerebral oxygenation, brain's activity and concentration performance.

NCT ID: NCT03301506 Recruiting - Clinical trials for Primary Biliary Cirrhosis

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Start date: December 12, 2017
Phase: Phase 3
Study type: Interventional

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

NCT ID: NCT03300492 Recruiting - Clinical trials for Acute Myeloid Leukemia

Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS

Start date: November 12, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The study examines the application of expanded natural killer cells (NK cells) following haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT) for AML or MDS. Haplo-HSCT is a preferred treatment option for patients with AML or MDS without a HLA-matched donor. With administration of cyclophosphamide post-transplant , the safety of the procedure is similar to a HSCT from a HLA-identical donor. Relapse of AML/MDS represents a serious problem following haplo-HSCT. NK cells are immune cells able to destroy tumor cells. Their potency has been established particularly in the setting of a haplo-HSCT. In the current study, study participants undergoing haplo-HSCT will receive expanded NK cells from their respective stem-cell donors following haplo-HSCT. The primary goal of the study is to establish the safety and feasibility of this approach. In addition, the activity of the NK cells will be examined.

NCT ID: NCT03300479 Withdrawn - Clinical trials for Nontraumatic Intracerebral Hemorrhage, Multiple Localized

Clevidipine (Cleviprex®) Compared With Urapidil (Ebrantil®)

Clevidipine
Start date: June 15, 2017
Phase: Phase 4
Study type: Interventional

Intracerebral hemorrhage (ICH) is responsible for 10-15% of primary strokes. ICH is a dynamic process with three phases: initial hemorrhage, followed by hematoma expansion and perihematoma edema formation. Hematoma volume is correlated with disease progression and outcome. Contemporary evidence proposes that elevated blood pressure is associated with hematoma expansion while more than 90% of patients with ICH present with acute hypertension. Uncontrolled blood pressure is a leading cause of ICH and it seems also to be a factor of poorer outcomes. Therefore, rapid reduction and control of blood pressure might ease disease progression and improve the outcome. Clevidipine (Cleviprex®), an ultrashort-acting dihydropyridine calcium channel antagonist, with its rapid onset and short duration might be more effective than conventional antihypertensives to achieve rapid blood pressure control in patients with acute ICH.

NCT ID: NCT03300089 Completed - Clinical trials for Herniated Disk Lumbar

Lumbar Spine Surgery: Regional vs. General Anaesthesia

Start date: January 19, 2016
Phase: N/A
Study type: Interventional

Background: Lumbar spine surgery can be performed using different anaesthetic techniques such as general endotracheal anaesthesia (GA) or spinal-based regional anaesthesia (RA), that have different side effect profiles (e.g. opioids - nausea, vomiting, pruritus, sedation; local anaesthetics - motor weakness) which may affect quality of recovery in different ways. Aim of the study: The purpose of this study is to determine the effects of GA and RA in lumbar spine surgery on clinical outcome, combining validated patient-reporting instruments and morbidity such as serious adverse events. Hypothesis: The investigators hypothesize that in patients undergoing lumbar spine surgery, RA shows significant advantages as compared to GA with respect to the postoperative pain score, the degree of postoperative nausea and vomiting (PONV), the postoperative anaesthetic care unit (PACU) and anaesthesia time and the satisfaction of patients and surgeons. Design of the study: This is a single-centre two-arm randomised-controlled trail.

NCT ID: NCT03298412 Terminated - Clinical trials for High-risk Diffuse Large B-cell Lymphoma

Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)

Start date: May 23, 2018
Phase: Phase 2
Study type: Interventional

The study will estimate the MRD-negative response rate after treatment with blinatumomab in subjects with high-risk DLBCL who are MRD-positive following aHSCT. The clinical hypothesis is that the MRD-negative response rate will be greater than 10%. Achieving an MRD-negative response rate of 30% would be of scientific and clinical interest.

NCT ID: NCT03297918 Completed - Heart Failure Clinical Trials

Impact of a Structural Phonation Training on Respiratory Muscle Function in Patients With Structural Heart Disease

Start date: February 15, 2018
Phase: N/A
Study type: Interventional

Most patients with complex congenital heart disease and cardiomyopathy from acquired heart disease have reduced exercise capacity. Exercise capacity is associated with respiratory muscle strength and function. If structured respiratory muscle training positively influences respiratory muscle function in patients with structural heart disease is not well known. The aim of this study is to investigate whether regular singing lessons and breathing exercises improve respiratory muscle strength in patients with congenital or acquired structural heart disease.

NCT ID: NCT03297593 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma

Start date: December 13, 2017
Phase: Phase 2
Study type: Interventional

Immunotherapy with checkpoint inhibitors that target PD-1 and CTLA-4 have shown activity in mRCC. However, the optimal schedule of the combination therapy has yet to be defined. The objective of the trial is to determine the efficacy of combination immunotherapy of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma. The expansion phase shall address the role of ipilimumab in case of clinically insignificant progression.

NCT ID: NCT03297437 Recruiting - Healthy Clinical Trials

Predictors for Successful Neurofeedback Training

Predictors
Start date: October 1, 2017
Phase: N/A
Study type: Interventional

The primary objective of this study is to identify predictors of neurofeedback training success.

NCT ID: NCT03297047 Completed - Radius Fractures Clinical Trials

Comparing Forearm and Upper Arm Combi Cast for Distal Forearm Fractures in Children

Start date: October 2, 2017
Phase: N/A
Study type: Interventional

The standard treatment for children with closed reduction of displaced distal forearm fractures is an immobilization with an upper arm combicast. The hypothesis is that an forearm immobilization with combicast in children 4-16 years might be sufficient.